Moonlake Immunotherapeutics Ag
Clinical trials sponsored by Moonlake Immunotherapeutics Ag, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug trial aims to help teens with painful skin condition Results expected Sep 2026 (estimated)
- New hope for psoriatic arthritis sufferers: experimental drug sonelokimab enters final testing phase Results expected Jan 2027 (estimated)
- New drug sonelokimab aims to ease psoriatic arthritis pain Results expected Feb 2027 (estimated)
-
New shot could ease painful skin condition
Disease control CompletedThis study tested a drug called sonelokimab, given as a shot under the skin, in 422 adults with moderate to severe hidradenitis suppurativa (a painful skin condition causing boils and abscesses). Participants were randomly assigned to receive either the drug or a placebo for up t…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New shot could ease painful skin condition
Disease control CompletedThis study tested a drug called sonelokimab in 418 adults with moderate to severe hidradenitis suppurativa, a skin condition that causes painful lumps and abscesses. Participants received either the drug or a placebo injection for 16 weeks. The goal was to see if sonelokimab redu…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Autoinjector vs. syringe: which delivers sonelokimab better?
Knowledge-focused CompletedThis study in 120 healthy adults compared two methods of giving a single dose of sonelokimab: a prefilled syringe and an autoinjector. The goal was to see if both methods deliver the same amount of drug into the body. Researchers measured drug levels in the blood and checked for …
Phase 1 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Phase 2, randomized, parallel-group, double-blind, placebo-controlled study of sonelokimab in patients with active moderate to severe hidradenitis suppurativa
CompletedThis is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
Phase 2 • Sponsor: MoonLake Immunotherapeutics AG
Last updated Sep 10, 2026 04:00 UTC